Budget Office Savings Estimates For Follow-On Biologics May Be Modest – McClellan
This article was originally published in The Pink Sheet Daily
Executive Summary
Follow-on biologics savings estimates by the Congressional Budget Office could “take some wind out of the sails” to develop legislation, the former FDA commissioner says.
You may also be interested in...
Follow-on Biologics Get Modest Savings Score From CBO, Giving Legislation No Push
Congressional Budget Office projects follow-on products could capture 35 percent of market with 40 percent lower price tag.
Follow-on Biologics Get Modest Savings Score From CBO, Giving Legislation No Push
Congressional Budget Office projects follow-on products could capture 35 percent of market with 40 percent lower price tag.
Insmed Takes Follow-On Biologics Push To The Web
Not enough understanding of debate, says Insmed exec; economic study to come